Q&A: Sage Launches Open Access Bionetwork Platform to Kickstart Drug Discovery

Merck's Eric Schadt discusses Sage, a new nonprofit that aims to build an open-access research platform to integrate human biological networks, predictive computational network models, and annotated information on human disease

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.